Related Experiment Videos
Intranasal immunization with inactivated influenza vaccine
1Sheffield Institute for Vaccine Studies, Division of Molecular and Genetic Medicine and Division of Child Health, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK.
Pharmaceutical Science & Technology Today
|September 28, 1999
Summary
Developing intranasal inactivated influenza vaccines is a promising strategy to overcome limitations of traditional vaccines. This research explores novel intranasal vaccine approaches for better epidemic and pandemic influenza control.
Area of Science:
- Vaccinology
- Virology
- Immunology
Background:
- Influenza virus infections pose significant epidemic and pandemic threats.
- Current injectable inactivated vaccines are cost-effective but have limitations.
- Live influenza vaccines face licensing hurdles due to safety concerns.
Purpose of the Study:
- To review recent developments in intranasal inactivated influenza vaccines.
- To explore alternative vaccine strategies for influenza control.
- To highlight the potential of intranasal vaccine delivery.
Main Methods:
- Review of scientific literature on intranasal vaccine development.
- Analysis of newer vaccine technologies like DNA and reverse genetics-derived vaccines.
- Focus on inactivated vaccines delivered intranasally with carriers or adjuvants.
Main Results:
- Intranasal administration of inactivated vaccines shows promise.
- Combining vaccines with carriers or adjuvants may enhance efficacy.
- Newer technologies offer potential future solutions.
Conclusions:
- Intranasal inactivated influenza vaccines represent an advantageous approach.
- Further vigorous research into intranasal vaccine strategies is warranted.
- This approach could improve epidemic and pandemic influenza preparedness.